{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:17:00Z","timestamp":1791389820894,"version":"4.3.3"},"reference-count":105,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.rpth.2024.102393","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:16:07Z","timestamp":1711548967000},"page":"102393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cancer and arterial thrombosis: therapeutic options"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-6596","authenticated-orcid":false,"given":"May Anne","family":"Cheong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-345X","authenticated-orcid":false,"given":"Avi","family":"Leader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102393_bib1","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1538-7836.2003.00501.x","article-title":"Malignancy, thrombosis and Trousseau: the case for an eponym","volume":"1","author":"Khorana","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaccao.2021.02.007","article-title":"Arterial thromboembolism in cancer patients: a Danish population-based cohort study","volume":"3","author":"Mulder","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2024.102393_bib4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102393_bib5","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102393_bib6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/jth.12265","article-title":"Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management","volume":"11","author":"Casini","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib7","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood.2020010116","article-title":"How I treat dysfibrinogenemia","volume":"138","author":"Casini","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102393_bib8","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102393_bib9","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2012.01.005","article-title":"Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden","volume":"48","author":"Zoller","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rpth.2024.102393_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2022.04.016","article-title":"Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: a prospective cohort study","volume":"214","author":"Noumegni","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102393_bib11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"Arterial ischemic events are a major complication in cancer patients with venous thromboembolism","volume":"131","author":"Brenner","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2024.102393_bib12","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1161\/STROKEAHA.111.615534","article-title":"Lung cancer and incidence of stroke: a population-based cohort study","volume":"42","author":"Chen","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102393_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.rpth.2024.102393_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaccao.2023.01.009","article-title":"Tumor genomic profile is associated with arterial thromboembolism risk in patients with solid cancer","volume":"5","author":"Feldman","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2024.102393_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2011.09.015","article-title":"Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden","volume":"48","author":"Zoller","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rpth.2024.102393_bib16","article-title":"Temporal trends in the prevalence of cancer and its impact on outcome in patients with first myocardial infarction: a nationwide study","volume":"9","author":"Velders","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.rpth.2024.102393_bib17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.11.016","article-title":"Trends in cancer diagnoses among inpatients hospitalized with stroke","volume":"22","author":"Sanossian","year":"2013","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.rpth.2024.102393_bib18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.mayocp.2020.05.045","article-title":"Incidence and risk of various types of arterial thromboembolism in patients with cancer","volume":"96","author":"Wang","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rpth.2024.102393_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.amjcard.2007.02.083","article-title":"Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry)","volume":"100","author":"Abbott","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rpth.2024.102393_bib20","doi-asserted-by":"crossref","first-page":"e993","DOI":"10.1212\/WNL.0000000000013316","article-title":"Clinical outcome after endovascular treatment in patients with active cancer and ischemic stroke: A MR CLEAN Registry Substudy","volume":"98","author":"Verschoof","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.rpth.2024.102393_bib21","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1212\/01.WNL.0000129912.56486.2B","article-title":"Stroke in patients with cancer: incidence and etiology","volume":"62","author":"Cestari","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.rpth.2024.102393_bib22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2024.102393_bib23","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0035-1564040","article-title":"Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer","volume":"41","author":"Falanga","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102393_bib24","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rpth.2024.102393_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor: an essential mediator of hemostasis and trigger of thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102393_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677040","article-title":"Neutrophil extracellular traps in arterial and venous thrombosis","volume":"45","author":"Laridan","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102393_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2019.06.919","article-title":"The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis","volume":"288","author":"Moschonas","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.rpth.2024.102393_bib28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.2184","article-title":"Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases","volume":"16","author":"Massberg","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2024.102393_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.thromres.2016.01.009","article-title":"NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation","volume":"139","author":"Thalin","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102393_bib30","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy-associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102393_bib31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rpth.2024.102393_bib32","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/bloodadvances.2019000034","article-title":"Ponatinib treatment promotes arterial thrombosis and hyperactive platelets","volume":"3","author":"Merkulova","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102393_bib33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102393_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001849","article-title":"Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience","volume":"8","author":"Batra","year":"2021","journal-title":"Open Heart"},{"key":"10.1016\/j.rpth.2024.102393_bib35","doi-asserted-by":"crossref","first-page":"18531","DOI":"10.1002\/cam4.6455","article-title":"Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: a retrospective cohort study","volume":"12","author":"Zhu","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.rpth.2024.102393_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1126\/science.1060191","article-title":"Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice","volume":"293","author":"Paris","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.rpth.2024.102393_bib37","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/hed.26102","article-title":"Prevalence of carotid stenosis following radiotherapy for head and neck cancer: a systematic review and meta-analysis","volume":"42","author":"Texakalidis","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.rpth.2024.102393_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-015-1732-2","article-title":"Review of cranial radiotherapy-induced vasculopathy","volume":"122","author":"Murphy","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2024.102393_bib39","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0049-3848(20)30396-0","article-title":"Genes and proteins associated with the risk for cancer-associated thrombosis","volume":"191","author":"Buijs","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102393_bib40","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jtho.2020.04.033","article-title":"Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC","volume":"15","author":"Al-Samkari","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.rpth.2024.102393_bib41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1055\/s-2006-933341","article-title":"Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy","volume":"32","author":"Rak","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102393_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100193","article-title":"Illustrated state-of-the-art capsules of the ISTH 2023 congress","volume":"7","author":"Kahn","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1753944712474332","article-title":"Chemotherapy-related cardiotoxicity","volume":"7","author":"Aggarwal","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.rpth.2024.102393_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A\u00a0systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.rpth.2024.102393_bib45","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1161\/CIRCULATIONAHA.111.037283","article-title":"Mechanisms of coronary artery spasm","volume":"124","author":"Lanza","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102393_bib46","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/HCO.0000000000000969","article-title":"Update on cancer therapy-induced atherosclerosis","volume":"37","author":"Reeves","year":"2022","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.rpth.2024.102393_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2020.04.050","article-title":"Acute myocardial infarction in a high-risk cancer population: outcomes following conservative versus invasive management","volume":"313","author":"Balanescu","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rpth.2024.102393_bib48","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.rpth.2024.102393_bib49","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102393_bib50","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2217\/fon-2017-0543","article-title":"Statins use and cancer: an update","volume":"14","author":"Zaleska","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.rpth.2024.102393_bib51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/clc.22007","article-title":"Treatment and outcomes of acute coronary syndrome in the cancer population","volume":"35","author":"Yusuf","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.rpth.2024.102393_bib52","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib53","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ccd.26379","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.rpth.2024.102393_bib54","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.rpth.2024.102393_bib55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaccao.2019.11.001","article-title":"Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention","volume":"1","author":"Ueki","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2024.102393_bib56","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/eurheartj\/ehy769","article-title":"Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States","volume":"40","author":"Potts","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102393_bib57","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.jcin.2017.06.068","article-title":"Re-evaluating the safety of drug-eluting stents in cancer patients","volume":"10","author":"Ganatra","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.rpth.2024.102393_bib58","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jacc.2007.11.061","article-title":"Subacute coronary stent thrombosis in cancer patients","volume":"51","author":"Gross","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102393_bib59","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijcard.2019.11.132","article-title":"Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor","volume":"301","author":"Bianco","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rpth.2024.102393_bib60","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102393_bib61","doi-asserted-by":"crossref","first-page":"e2477","DOI":"10.1212\/WNL.0000000000207341","article-title":"Clinical and demographic characteristics, mechanisms, and outcomes in patients with acute ischemic stroke and newly diagnosed or known active cancer","volume":"100","author":"Costamagna","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.rpth.2024.102393_bib62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ana.22050","article-title":"Coagulopathy and embolic signal in cancer patients with ischemic stroke","volume":"68","author":"Seok","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.rpth.2024.102393_bib63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ana.26129","article-title":"Mechanisms of ischemic stroke in patients with cancer: a prospective study","volume":"90","author":"Navi","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.rpth.2024.102393_bib64","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/STROKEAHA.123.044910","article-title":"Coagulation factor expression and composition of arterial thrombi in cancer-associated stroke","volume":"54","author":"Yoo","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102393_bib65","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102393_bib66","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2024.102393_bib67","article-title":"Prevalence and overlap of potential embolic sources in patients with embolic stroke of undetermined source","volume":"8","author":"Ntaios","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.rpth.2024.102393_bib68","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/STROKEAHA.120.032002","article-title":"Cancer and embolic stroke of undetermined source","volume":"52","author":"Navi","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102393_bib69","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.amjmed.2020.06.047","article-title":"A\u00a0contemporary 20-year Cleveland clinic experience of nonbacterial thrombotic endocarditis: etiology, echocardiographic imaging, management, and outcomes","volume":"134","author":"Zmaili","year":"2021","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2024.102393_bib70","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/j.thromres.2021.11.024","article-title":"Cancer-associated non-bacterial thrombotic endocarditis","volume":"213","author":"Itzhaki Ben Zadok","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102393_bib71","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102393_bib72","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jns.2012.12.008","article-title":"Intravenous alteplase for acute ischemic stroke in patients with current malignant neoplasm","volume":"325","author":"Cappellari","year":"2013","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.rpth.2024.102393_bib73","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/ijcp.12586","article-title":"Safety of intravenous thrombolysis for acute ischaemic stroke including concomitant neoplastic disease sufferers - experience from Poland","volume":"69","author":"Sobolewski","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.rpth.2024.102393_bib74","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1591019918776207","article-title":"Procedural and clinical outcomes of endovascular recanalization therapy in patients with cancer-related stroke","volume":"24","author":"Jung","year":"2018","journal-title":"Interv Neuroradiol"},{"key":"10.1016\/j.rpth.2024.102393_bib75","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMc1809065","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"379","author":"Harloff","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102393_bib76","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"Diener","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102393_bib77","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ene.14172","article-title":"Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial","volume":"27","author":"Martinez-Majander","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.rpth.2024.102393_bib78","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer","volume":"83","author":"Navi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.rpth.2024.102393_bib79","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.thromres.2023.05.017","article-title":"Arterial events in cancer patients treated with apixaban for venous thrombosis","volume":"228","author":"Larsen","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102393_bib80","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.117.032617","article-title":"Risk and prognosis of cancer after lower limb arterial thrombosis","volume":"138","author":"Sundboll","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102393_bib81","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102393_bib82","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102393_bib83","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.115.016424","article-title":"Population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention","volume":"132","author":"Howard","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102393_bib84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jaccao.2022.11.019","article-title":"Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials","volume":"5","author":"Alexandre","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2024.102393_bib85","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaccao.2021.08.011","article-title":"Common pathophysiology in cancer, atrial fibrillation, atherosclerosis, and thrombosis: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Leiva","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2024.102393_bib86","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaccao.2022.08.014","article-title":"Arterial thromboembolism in patients with AF and CHA(2)DS(2)-VASc Score 0-2 with and without cancer","volume":"5","author":"Leader","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2024.102393_bib87","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaccao.2023.04.003","article-title":"Anticoagulation for the prevention of arterial thrombosis in ambulatory cancer patients: systematic review and meta-analysis","volume":"5","author":"Xu","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2024.102393_bib88","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjcard.2022.06.044","article-title":"Validation of embolic and bleeding risk scores in patients with atrial fibrillation and cancer","volume":"180","author":"Raposeiras-Roubin","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rpth.2024.102393_bib89","article-title":"Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA(2)DS(2)VASC score: CCHA(2)DS(2)VASC score","volume":"41","author":"Bungo","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.rpth.2024.102393_bib90","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"Navi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102393_bib91","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/jth.15600","article-title":"Previously undiagnosed cancer in patients with arterial thrombotic events - a population-based cohort study","volume":"20","author":"Leader","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib92","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.5002","article-title":"Association of stroke at young age with new cancer in the years after stroke among patients in the Netherlands","volume":"6","author":"Verhoeven","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2024.102393_bib93","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12872-018-0932-z","article-title":"Incidence of new onset cancer in patients with a myocardial infarction - a nationwide cohort study","volume":"18","author":"Malmborg","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.rpth.2024.102393_bib94","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2542-5196(21)00081-4","article-title":"Global, regional, and national burden of mortality associated with non-optimal ambient temperatures from 2000 to 2019: a three-stage modelling study","volume":"5","author":"Zhao","year":"2021","journal-title":"Lancet Planet Health"},{"key":"10.1016\/j.rpth.2024.102393_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.101743","article-title":"PB0946 risk of venous and arterial thromboembolism in recurrent\/ metastatic colorectal cancer patients receiving first-line cetuximab-based combination therapy: a Korean population-based study","volume":"7","author":"Yhim","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.101757","article-title":"PB0929 genetic aberrations create different procoagulant landscapes across cancers","volume":"7","author":"Tawil","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100603","article-title":"OC 46.4 association of growth differentiation factor-15 (GDF-15) with thromboembolism and mortality in patients with cancer: findings from the Vienna Cats Study","volume":"7","author":"Nopp","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100928","article-title":"PB0121 relationship of thrombo-inflammatory biomarkers with oxidative stress level in non-small cell lung cancer patients","volume":"7","author":"Nikolovski","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.101306","article-title":"PB0707 neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress","volume":"7","author":"Cedervall","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100310","article-title":"OC 03.5 arterial events in cancer patients treated with apixaban for venous thrombosis","volume":"7","author":"Larsen","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100302","article-title":"OC 74.3 anticoagulant use and prognosis in patients with atrial fibrillation and cancer: a nationwide population-based study","volume":"7","author":"Chen","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100765","article-title":"PB0546 effect of atorvastatin on IL-6 and F1+2 in high risk thrombosis patients with cancer undergoing chemotherapy","volume":"7","author":"Setiawan","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib104","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1182\/bloodadvances.2020003269","article-title":"A\u00a0toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies","volume":"4","author":"Siegal","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102393_bib105","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102393_bib106","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/jth.14484","article-title":"Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer","volume":"17","author":"Grilz","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102393_bib107","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology Guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J\u00a0Am Heart Assoc"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T07:09:17Z","timestamp":1717398557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2475037924000827"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102393","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer and arterial thrombosis: therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102393"}}